KANABO GROUP PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.7 GBX | 0.00% |
|
+2.10% | -39.29% |
| 03-28 | Kanabo shares soar after company announces UK mental health service | AN |
| 03-28 | Kanabo Group plc Announces Expansion of Treat It Clinic to Offer Mental Health Treatments | CI |
| Sales 2021 | 73K 91.19K 7.3M | Sales 2022 | 603K 753K 60.3M | Capitalization | 8.04M 10.04M 804M |
|---|---|---|---|---|---|
| Net income 2021 | -4M -5M -400M | Net income 2022 | -6M -7.5M -600M | EV / Sales 2021 | 648 x |
| Net cash position 2021 | 4.5M 5.62M 450M | Net cash position 2022 | 3.01M 3.76M 301M | EV / Sales 2022 | 8.33 x |
| P/E ratio 2021 |
-9.98
x | P/E ratio 2022 |
-1.15
x | Employees | 23 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 50.93% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | +2.10% | ||
| Current month | -2.86% | ||
| 1 month | -5.56% | ||
| 3 months | -17.07% | ||
| 6 months | +28.30% | ||
| Current year | -39.29% |
1 week
1.50
1.90
1 month
1.502.00
Current year
1.503.20
1 year
1.153.52
3 years
1.1526.00
5 years
1.1551.00
10 years
1.1551.00
| Managers | Title | Age | Since |
|---|---|---|---|
Avihu Tamir
CEO | Chief Executive Officer | - | - |
Assaf Vardimon
DFI | Director of Finance/CFO | 46 | - |
Ophir Shimshi
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ian Mattioli
CHM | Chairman | 62 | 08/05/23 |
David Tsur
BRD | Director/Board Member | 73 | 27/06/21 |
Sharon Malka
BRD | Director/Board Member | 51 | 03/05/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.7 | 0.00% | 88,875 |
| 25/04/24 | 1.7 | 0.00% | 184,261 |
| 24/04/24 | 1.7 | 0.00% | 659,584 |
| 23/04/24 | 1.7 | -2.86% | 156,402 |
| 22/04/24 | 1.75 | +5.11% | 485,346 |
Delayed Quote London S.E., April 26, 2024 at 04:35 pm
More quotes
Kanabo Group plc is a United Kingdom-based patient-focused provider of digital health services and specialist medicines, including medicinal cannabis. The Companyâs principal activities are the distribution and development of cannabis derived medical and wellness products. The Company is focused on the distribution of cannabis-derived products for medical patients, and non- tetrahydrocannabinol (THC) products for cannabidiol (CBD) consumers. It has conducted research and development (R&D) in order to develop cannabis extract formulas, medical-grade vaporizers and various non-smoking consumption solutions. Its clinical and validation activities, including safety and efficiency tests, are conducted in Israel. The Company operates through two segments: Primary case and Secondary case. Primary case segment is involved in the telepharma services provided by GPS. Secondary case segment is involved in the distribution and development of cannabis-derived medical and wellness products.
Sector
Pharmaceuticals
Calendar
29/04/2024
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -39.29% | 13.39M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- KNB Stock
